Show simple item record

dc.contributor.authorCox, H*
dc.contributor.authorFord, N*
dc.contributor.authorKeshavjee, S*
dc.contributor.authorMcDermid, C*
dc.contributor.authorvon Schoen-Angerer, T*
dc.contributor.authorMitnick, C*
dc.contributor.authorGoemaere, E*
dc.date.accessioned2011-05-23T19:38:52Z
dc.date.available2011-05-23T19:38:52Z
dc.date.issued2011-04-01
dc.date.submitted2011-04-29
dc.identifier.citationLancet Infect Dis 2011;11(4):259-60en
dc.identifier.issn1474-4457
dc.identifier.pmid21453864
dc.identifier.doi10.1016/S1473-3099(11)70036-6
dc.identifier.urihttp://hdl.handle.net/10144/129952
dc.language.isoenen
dc.relation.urlhttp://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70036-6/fulltext?_eventId=loginen
dc.rightsPublished by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/journals/laninf[/url] for further relevant comment.en
dc.subject.meshTuberculosisen
dc.subject.meshTuberculosis, Multidrug-Resistanten
dc.subject.meshMoxifloxacinen
dc.titleRational use of moxifloxacin for tuberculosis treatmenten
dc.typeArticleen
dc.contributor.departmentBurnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerlanden
dc.identifier.journalLancet Infectious Diseasesen
refterms.dateFOA2019-03-04T08:45:04Z


Files in this item

Thumbnail
Name:
110401_Cox_Rational-Use-of-Mox ...
Size:
40.05Kb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record